These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30395156)

  • 1. Reply to the letter to the editor 'Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting' by van der Galiën et al.
    Maurer MJ; Habermann TM
    Ann Oncol; 2019 Jan; 30(1):153. PubMed ID: 30395156
    [No Abstract]   [Full Text] [Related]  

  • 2. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting.
    van der Galiën HT; Hoogendoorn M; Kibbelaar RE; van Meerten T; van Rijn RS
    Ann Oncol; 2019 Jan; 30(1):151-152. PubMed ID: 30364941
    [No Abstract]   [Full Text] [Related]  

  • 3. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.
    Maurer MJ; Habermann TM; Shi Q; Schmitz N; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Haioun C; Tilly H; Ghesquieres H; Merli F; Ziepert M; Herbrecht R; Flament J; Fu T; Flowers CR; Coiffier B
    Ann Oncol; 2018 Aug; 29(8):1822-1827. PubMed ID: 29897404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
    Shi Q; Schmitz N; Ou FS; Dixon JG; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Habermann TM; Haioun C; Tilly H; Ghesquieres H; Merli F; Ziepert M; Herbrecht R; Flament J; Fu T; Coiffier B; Flowers CR
    J Clin Oncol; 2018 Sep; 36(25):2593-2602. PubMed ID: 29975624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardized Definition of Progression-Free Survival in Diffuse Large B-Cell Lymphoma Is Urgently Needed.
    Adams HJA; Kwee TC
    J Clin Oncol; 2019 Feb; 37(6):525-526. PubMed ID: 30592639
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to H.J.A. Adams et al.
    Shi Q; Flowers CR
    J Clin Oncol; 2019 Feb; 37(6):526-527. PubMed ID: 30592641
    [No Abstract]   [Full Text] [Related]  

  • 7. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.
    Colosia A; Njue A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):343-355.e6. PubMed ID: 24768510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis.
    Zhou X; Ma T; Zhang Y; Zhou N; Li J
    PLoS One; 2017; 12(3):e0174648. PubMed ID: 28355276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma.
    Liu P; Han Y; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Zhou LQ; Yang JL; Yang S; Wen TY; Shi YK
    Chin Med J (Engl); 2019 Aug; 132(15):1807-1814. PubMed ID: 31335477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H
    Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP.
    Mondello P; Mian M
    Hematol Oncol; 2019 Oct; 37(4):333-344. PubMed ID: 30938848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.
    Cho KM; Keam B; Ha H; Kim M; Jung JW; Song WJ; Kim TM; Jeon YK; Kang HR; Kim DW; Kim CW; Heo DS
    Korean J Intern Med; 2019 Jul; 34(4):885-893. PubMed ID: 29151283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
    Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
    Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis.
    Ren YR; Jin YD; Zhang ZH; Li L; Wu P
    Chin Med J (Engl); 2015 Feb; 128(3):378-83. PubMed ID: 25635435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
    Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
    EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA.
    Morrison VA; Shou Y; Bell JA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Eaddy M; Galaznik A
    Future Oncol; 2019 Mar; 15(9):1021-1034. PubMed ID: 30757910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of survival and treatment outcome of patients with primary diffuse large B cell lymphoma in reproductive system].
    Yang P; Zhen JF; Pang M; Hu K; Zhao W; Dong F; Tian L; Ke XY; Jing HM
    Zhonghua Yi Xue Za Zhi; 2018 May; 98(20):1593-1596. PubMed ID: 29886651
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.